# A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer

> **NCT00808418** · PHASE1 · COMPLETED · sponsor: **Synta Pharmaceuticals Corp.** · enrollment: 34 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Elesclomol Sodium
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00808418
- **Lead sponsor:** Synta Pharmaceuticals Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2014-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00808418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00808418, "A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00808418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*